•
Sep 30, 2024
NeueHealth Q3 2024 Earnings Report
Delivered strongest financial performance driven by NeueCare and NeueSolutions, achieving positive Adjusted EBITDA for the third consecutive quarter and reaffirming full-year Adjusted EBITDA guidance.
Key Takeaways
NeueHealth reported strong financial results for Q3 2024, driven by positive momentum in NeueCare and NeueSolutions. The company achieved Adjusted EBITDA profitability for the third consecutive quarter and reaffirmed its full-year Adjusted EBITDA guidance.
Delivered strongest financial performance to date in Q3 ‘24, resulting from continued positive momentum in NeueCare and NeueSolutions business segments
Drove positive Adjusted EBITDA for the third consecutive quarter in 2024
Reaffirming Adjusted EBITDA guidance for the full year
Well-positioned to build on success and capitalize on strategic growth opportunities in 2025 and beyond
NeueHealth
NeueHealth
Forward Guidance
NeueHealth reaffirms its financial outlook for 2024.
Positive Outlook
- Revenue is expected to be approximately $950 million
- NeueCare Revenue is expected to be approximately $320 million
- NeueSolutions Revenue is expected to be approximately $640 million
- Adjusted Operating Cost Ratio is expected to be between 15% and 16%, excluding corporate costs.
- Including corporate costs, this is expected to be between 19% and 20%
- Adjusted EBITDA is expected to be between $15 million and $25 million in 2024